Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Appreciated Media Holdings Inc. stock logo
AMEFF
Appreciated Media
$0.02
$0.01
$0.05
N/AN/A63,600 shs37,900 shs
Bally Technologies stock logo
BYI
Bally Technologies
$0.00
$56.50
$84.66
N/AN/A839,983 shsN/A
CTS Eventim AG & Co. KGaA stock logo
CEVMF
CTS Eventim AG & Co. KGaA
$86.55
$72.66
$58.95
$89.98
N/AN/A140 shs14 shs
EEGI
Eline Entertainment Group
0.00
0.00
0.00
0.00
N/AN/A1.56 million shs33,300 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$64.91
-0.6%
$71.40
$64.88
$87.86
$80.82B0.197.34 million shs1.89 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Appreciated Media Holdings Inc. stock logo
AMEFF
Appreciated Media
0.00%0.00%0.00%0.00%0.00%
CTS Eventim AG & Co. KGaA stock logo
CEVMF
CTS Eventim AG & Co. KGaA
0.00%-1.70%+25.62%+25.41%+35.62%
EEGI
Eline Entertainment Group
0.00%0.00%0.00%0.00%-66.67%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-2.70%-1.35%-9.86%-17.92%-22.06%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Appreciated Media Holdings Inc. stock logo
AMEFF
Appreciated Media
N/AN/AN/AN/AN/AN/AN/AN/A
Bally Technologies stock logo
BYI
Bally Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CTS Eventim AG & Co. KGaA stock logo
CEVMF
CTS Eventim AG & Co. KGaA
N/AN/AN/AN/AN/AN/AN/AN/A
EEGI
Eline Entertainment Group
N/AN/AN/AN/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.9992 of 5 stars
4.25.04.24.12.92.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Appreciated Media Holdings Inc. stock logo
AMEFF
Appreciated Media
N/AN/AN/AN/A
Bally Technologies stock logo
BYI
Bally Technologies
N/AN/AN/AN/A
CTS Eventim AG & Co. KGaA stock logo
CEVMF
CTS Eventim AG & Co. KGaA
3.00
BuyN/AN/A
EEGI
Eline Entertainment Group
N/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.33
Hold$84.5730.29% Upside

Current Analyst Ratings

Latest GILD, AMEFF, BYI, CEVMF, and EEGI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/24/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeReduce ➝ Hold$69.00
4/19/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00
4/17/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$81.00 ➝ $75.00
3/4/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$84.00 ➝ $77.00
2/22/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$101.00 ➝ $90.00
2/22/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$91.00 ➝ $82.00
2/14/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$76.00 ➝ $75.00
2/12/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$85.00 ➝ $80.00
2/12/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$115.00 ➝ $105.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Appreciated Media Holdings Inc. stock logo
AMEFF
Appreciated Media
N/AN/AN/AN/AN/AN/A
Bally Technologies stock logo
BYI
Bally Technologies
N/AN/AN/AN/AN/AN/A
CTS Eventim AG & Co. KGaA stock logo
CEVMF
CTS Eventim AG & Co. KGaA
N/AN/AN/AN/AN/AN/A
EEGI
Eline Entertainment Group
N/AN/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.12B2.98$8.65 per share7.50$18.26 per share3.55

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Appreciated Media Holdings Inc. stock logo
AMEFF
Appreciated Media
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Bally Technologies stock logo
BYI
Bally Technologies
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CTS Eventim AG & Co. KGaA stock logo
CEVMF
CTS Eventim AG & Co. KGaA
N/AN/A0.00N/AN/AN/AN/AN/A
EEGI
Eline Entertainment Group
N/A0.030.00N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$5.67B$4.5014.428.931.2020.89%38.85%13.60%N/A

Latest GILD, AMEFF, BYI, CEVMF, and EEGI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/25/2024Q1 2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$1.49-$1.32+$0.17$0.70$6.36 billion$6.69 billion    
2/6/2024Q4 23
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.76$1.72-$0.04$2.30$7.10 billion$7.12 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Appreciated Media Holdings Inc. stock logo
AMEFF
Appreciated Media
N/AN/AN/AN/AN/A
Bally Technologies stock logo
BYI
Bally Technologies
N/AN/AN/AN/AN/A
CTS Eventim AG & Co. KGaA stock logo
CEVMF
CTS Eventim AG & Co. KGaA
N/AN/AN/AN/AN/A
EEGI
Eline Entertainment Group
N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.084.75%+3.32%68.44%9 Years

Latest GILD, AMEFF, BYI, CEVMF, and EEGI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/1/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Quarterly$0.774.14%3/14/20243/15/20243/28/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Appreciated Media Holdings Inc. stock logo
AMEFF
Appreciated Media
N/AN/AN/A
Bally Technologies stock logo
BYI
Bally Technologies
N/AN/AN/A
CTS Eventim AG & Co. KGaA stock logo
CEVMF
CTS Eventim AG & Co. KGaA
N/AN/AN/A
EEGI
Eline Entertainment Group
N/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.08
1.43
1.27

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Appreciated Media Holdings Inc. stock logo
AMEFF
Appreciated Media
N/AN/AN/ANot Optionable
Bally Technologies stock logo
BYI
Bally Technologies
N/AN/AN/ANot Optionable
CTS Eventim AG & Co. KGaA stock logo
CEVMF
CTS Eventim AG & Co. KGaA
3,535N/AN/ANot Optionable
EEGI
Eline Entertainment Group
4N/AN/ANot Optionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
18,0001.25 billion1.24 billionOptionable

GILD, AMEFF, BYI, CEVMF, and EEGI Headlines

SourceHeadline
Gilead Sciences (NASDAQ:GILD) Receives "Hold" Rating from Needham & Company LLCGilead Sciences (NASDAQ:GILD) Receives "Hold" Rating from Needham & Company LLC
marketbeat.com - April 26 at 8:43 AM
Gilead: Q1 Earnings SnapshotGilead: Q1 Earnings Snapshot
washingtonpost.com - April 26 at 7:34 AM
Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
finance.yahoo.com - April 26 at 7:34 AM
Zacks Research Research Analysts Lower Earnings Estimates for Gilead Sciences, Inc. (NASDAQ:GILD)Zacks Research Research Analysts Lower Earnings Estimates for Gilead Sciences, Inc. (NASDAQ:GILD)
americanbankingnews.com - April 26 at 1:38 AM
Dow Inc. Q1 Earnings SummaryDow Inc. Q1 Earnings Summary
markets.businessinsider.com - April 25 at 9:33 PM
Gilead’s quarterly loss is narrower than expectedGilead’s quarterly loss is narrower than expected
msn.com - April 25 at 9:33 PM
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q1 2024
investorplace.com - April 25 at 8:11 PM
Gilead Sciences (NASDAQ:GILD) Releases  Earnings Results, Beats Expectations By $0.17 EPSGilead Sciences (NASDAQ:GILD) Releases Earnings Results, Beats Expectations By $0.17 EPS
marketbeat.com - April 25 at 7:01 PM
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to SayGilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
zacks.com - April 25 at 7:01 PM
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue EstimatesGilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
zacks.com - April 25 at 6:16 PM
Gilead Beats Earnings Expectations After Rocky QuarterGilead Beats Earnings Expectations After Rocky Quarter
barrons.com - April 25 at 5:49 PM
Gilead Sciences (NASDAQ:GILD) Updates FY 2024 Earnings GuidanceGilead Sciences (NASDAQ:GILD) Updates FY 2024 Earnings Guidance
marketbeat.com - April 25 at 5:47 PM
Gilead Sciences Inc (GILD) Q1 2024 Earnings: Misses Analyst EPS Estimates Amid Significant ...Gilead Sciences Inc (GILD) Q1 2024 Earnings: Misses Analyst EPS Estimates Amid Significant ...
gurufocus.com - April 25 at 5:04 PM
Gilead posts quarterly loss, revenue rises 5%Gilead posts quarterly loss, revenue rises 5%
reuters.com - April 25 at 4:11 PM
Gilead Sciences Announces First Quarter 2024 Financial ResultsGilead Sciences Announces First Quarter 2024 Financial Results
businesswire.com - April 25 at 4:02 PM
Gilead Sciences (NASDAQ:GILD) Reaches New 12-Month Low at $65.61Gilead Sciences (NASDAQ:GILD) Reaches New 12-Month Low at $65.61
marketbeat.com - April 25 at 3:45 PM
Gilead Sciences Target of Unusually Large Options Trading (NASDAQ:GILD)Gilead Sciences Target of Unusually Large Options Trading (NASDAQ:GILD)
marketbeat.com - April 25 at 1:11 PM
Alaska Permanent Fund Corp Sells 25,031 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Alaska Permanent Fund Corp Sells 25,031 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
marketbeat.com - April 25 at 10:02 AM
Q1 2024 EPS Estimates for Gilead Sciences, Inc. (NASDAQ:GILD) Decreased by AnalystQ1 2024 EPS Estimates for Gilead Sciences, Inc. (NASDAQ:GILD) Decreased by Analyst
marketbeat.com - April 25 at 7:37 AM
Gilead Sciences (NASDAQ:GILD) Upgraded to "Hold" at HSBCGilead Sciences (NASDAQ:GILD) Upgraded to "Hold" at HSBC
americanbankingnews.com - April 25 at 6:15 AM
FY2024 EPS Estimates for Gilead Sciences, Inc. Decreased by Analyst (NASDAQ:GILD)FY2024 EPS Estimates for Gilead Sciences, Inc. Decreased by Analyst (NASDAQ:GILD)
americanbankingnews.com - April 25 at 4:02 AM
Gilead Sciences, Inc. (NASDAQ:GILD) Forecasted to Post Q2 2024 Earnings of $1.40 Per ShareGilead Sciences, Inc. (NASDAQ:GILD) Forecasted to Post Q2 2024 Earnings of $1.40 Per Share
americanbankingnews.com - April 25 at 2:30 AM
Bailard Inc. Sells 48,838 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Bailard Inc. Sells 48,838 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
marketbeat.com - April 24 at 11:39 PM
Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focusGilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus
msn.com - April 24 at 6:37 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Appreciated Media logo

Appreciated Media

OTCMKTS:AMEFF
Appreciated Media Holdings, Inc. is a worldwide film and television media production packager. It engages in producing independent films, made-for-television movies, and TV series for global B2B distribution. The company was founded by Kirk Edward Shaw, Tony Zhang, and Norman Tsui on October 1, 2014 and is headquartered in Hamilton, Canada.
Bally Technologies logo

Bally Technologies

NYSE:BYI
Bally Technologies, Inc. (Bally) is a global gaming company, which designs, manufactures, operates, and distributes advanced technology-based gaming devices, systems, server-based solutions, custom mobile applications, and interactive applications. The Company also provides hardware, including spinning-reel and video gaming devices, specialty gaming devices, and wide-area progressive systems. The Company supports customers include land-based, riverboat, and Native American casinos, video lottery and central determination markets. The Company derives its revenue from sale of gaming devices and related equipment, parts and conversion kits; operation of linked progressive systems, video lottery and centrally determined systems, and the rental of gaming devices and content, and sale and support of specialized systems-based software, hardware and interactive products and related recurring maintenance revenue. In July 2014, Bally Technologies Inc acquired Dragonplay Ltd. (Dragonplay).
CTS Eventim AG & Co. KGaA logo

CTS Eventim AG & Co. KGaA

OTCMKTS:CEVMF
CTS Eventim AG & Co. KGaA operates in the leisure events market in Germany, Italy, Switzerland, Austria, the United Kingdom, Sweden, the United States, Finland, Spain, Denmark, the Netherlands, and internationally. The company operates through two segments, Ticketing and Live Entertainment. The Ticketing segment produces, sells, brokers, distributes, and markets tickets for concerts, theatre, art, sports, and other events. It markets events (tickets) through EVENTIM.Web and using its network platform, EVENTIM.Net; in-house ticketing products through EVENTIM.Inhouse; sport ticketing products through EVENTIM.Tixx; and self-service products for promotors through EVENTIM.Light, as well as provides a solution for ticket sales and admission control through EVENTIM.Access. This segment also operates kinoheld software for cinema operators; EVENTIM.fanSALE, a resale portal where customers sell event tickets to other customers; and online portals under various brands, such as eventim.de, oeticket.com, ticketcorner.ch, ticketone.it, and entradas.com. The Live Entertainment segment plans, prepares, and performs tours, events, and festivals, including music events and concerts, as well as markets music productions. This segment is also involved in the operation of venues. The company was formerly known as CTS EVENTIM AG and changed its name to CTS Eventim AG & Co. KGaA in May 2014. CTS Eventim AG & Co. KGaA was founded in 1989 and is headquartered in Bremen, Germany.

Eline Entertainment Group

OTCMKTS:EEGI
Eline Entertainment Group, Inc., engages in the production and distribution of sports and entertainment activities. The company was incorporated in 1997 and is based in Admiralty, Hong Kong.
Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.